PLAINSBORO, N.J., July 13, 2011 (GLOBE NEWSWIRE) — Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced that it will release a line extension for its Uni-CP™ Compression System. The Uni-CP™ Compression System provides a comprehensive solution for arthrodesis and fracture management for mid and hindfoot reconstruction. The Uni-CP™ product line extension includes a 4-hole U-shape locking plate, designed for second and third metatarsal-cuneiform fusion. The Uni-CP™ Compression System has clearance from the Food and Drug Administration (FDA) in the United States and a CE Mark Certification in the European Union.
“The new line extension is a very exciting opportunity for Integra,” said Pete Ligotti, Vice President, Marketing, Integra Extremity Reconstruction. “The U-shape plate is an innovative approach to fixation of the second and third metatarsal cuneiform joints.�It comes in three sizes, which gives surgeons a significant addition to their armamentarium, and helps limit uncertainty by accommodating a patient’s unique treatment needs.”
The Uni-CP™ Compression System currently includes a line of compression plates designed for the correction and stabilization of osteotomies and fusions in the foot.�Each product employs a diamond shaped bridge design to provide compression through controlled deformation of the implant by the surgeon.�The Uni-CP™ Compression plates use Surfix® locking technology that enables the surgeon to place the plate at the optimal distance from the bone and then lock the screws.
The Uni-CP™ Compression System is sold by Integra’s Extremity Reconstruction sales organization, which focuses on lower extremity fixation, upper extremity fixation, tendon protection, peripheral nerve repair/protection and wound repair.�
Integra LifeSciences, a world leader in medical devices, is dedicated to limiting uncertainty for surgeons, so they can concentrate on providing the best patient care.� Integra offers innovative solutions in orthopedics, neurosurgery, spine, reconstructive, and general surgery. For more information, please visit www.integralife.com.
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.�Forward-looking statements include, but are not limited to, statements concerning the products and services provided by Integra.�Such forward looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results.�Among other things, the willingness of surgical professionals to use Integra products may affect the prospects for their use in surgical procedures.�In addition, the economic, competitive, governmental, technological and other factors, identified under the heading “Risk Factors” included in Item IA of Integra’s Annual Report on Form 10-K for the year ended December 31, 2010 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.
CONTACT: Integra LifeSciences Holdings Corporation
Gianna Sabella
Director, Corporate Communications
(609) 936-2389
gianna.sabella@integralife.com
http://bit.ly/nqPNPr
No comments:
Post a Comment